ArticleFrontiers in endocrinology2023

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis.

Shuhui You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.